Mary Caffrey

Pharmacy benefit managers (PBMs) will have to disclose some information about their compensation and relationships with payers.

The Institute for Value-Based Medicine travels to New York City to learn how technology and trust are key to making the leap to two-sided risk.

For 2017, New Jersey's largest insurer made particularly good progress in certain diabetes measures and in cancer screenings.

James P. Allison, PhD, and Tasuku Honjo, MD, PhD, led the basic science experiments that showed the potential of checkpoint inhibitors, creating a fourth pillar in the treatment of cancer.

POSTERS AT THE 2018 American Association of Diabetes Educators (AADE) Annual Conference covered updates on new therapies and technology, strategies to help patients overcome fear of using insulin, and innovations in diabetes self-management education and support. Following are a few snapshots of the research presented at AADE.

Loyola University Chicago and Loyola Medicine announced plans this week to develop their own chimeric antigen receptor T-cells that would have less toxic side effects.

Livongo’s technology is built around the idea that a person living with diabetes must make multiple decisions every day, and the cumulative effect of all those decisions drives outcomes.

A profile of a program that calls for residents in a rural area to become full partners in managing their type 2 diabetes, and in the process bring changes to their community.

Employers who have been disappointed in the past with wellness programs want to see evidence of patient engagement and how this translates into savings.

Advocates for keeping Medicare as it is were joined by a well-known pollster to discuss that voters are concerned about out-of-pocket costs, including what they pay for prescription drugs, as the 2018 midterm elections approach.

Heart failure hospitalization has been a target for accountable care organizations seeking to find ways to cut costs from the healthcare system. But it remains to be seen how many of the estimated 2 million patients would gain access to the device if it received an expanded indication and payer coverage.

Full results from the cardiovascular outcomes trial for dapagliflozin (Farxiga) will be presented at the American Heart Association annual meeting in November.

AARP and other groups reacted strongly to reports that the pharmaceutical industry was using efforts to combat the opioid crisis to roll back an agreement to close the coverage gap in Medicare Part D.

A series of experiments identified both "good" and "bad" gut bacteria, suggesting possible treatments for obesity.

The bill is part of President Donald Trump's blueprint to rein in prescription drug prices, and advocates see it as a small step in the right direction.

Lower socioeconomic status is associated with poor survival in lymphoma.

The study by the National Institute on Aging produced a few surprises and was stopped early when aspirin showed no benefit.

The announcement comes with word from FDA touting the effectiveness of its efforts to advance digital health regulatory pathways.

The application is based on results presented in March at the 67th Scientific Session of the American College of Cardiology.

One patient saw a complete response, and the therapy was well tolerated, especially compared with the adverse effects sometimes seen with chimeric antigen receptor (CAR) T-cell treatment in blood cancers thus far.

FDA's designation is based on phase 2 data presented earlier this year at the American Society of Clinical Oncology Annual Meeting.

The analysis of patient records found no elevated risk of retinopathy among those using glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes.

A leader at the Institute for Healthcare Improvement offers a framework for diabetes educators to embrace a shift in thinking about healthcare delivery.

Authors of a Health Affairs blog post cite an initiative that rates how well cities are doing in making sure their laws allow for affordable housing, which is getting more attention as a factor in population health.

Patients with type 2 diabetes and moderate renal impairment who took oral semaglutide in a phase 3a trial reported a larger reduction in glycated hemoglobin and more weight loss than patients taking placebo.

Three federal officials discussed the status of research, payer coverage, and referrals for the National Diabetes Prevention Program, as well as the rollout of the Medicare program for eligible seniors.

The rise of digital health alongside the transformation of reimbursement from fee-for-service to value-based care is allowing patients to fully participate in their own care, according to a leader with one of the top digital health companies in diabetes care.

Robert A. Gabbay, MD, PhD, FACP, chief medical officer and senior vice president at Joslin Diabetes Center, said health systems need people with the skill sets that diabetes educators possess to make the transition to a reimbursement system based on quality, prevention, and eliminating costs.